BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Corcos J, Przydacz M, Campeau L, Gray G, Hickling D, Honeine C, Radomski SB, Stothers L, Wagg A, Lond F. CUA guideline on adult overactive bladder. Can Urol Assoc J 2017;11:E142-73. [PMID: 28503229 DOI: 10.5489/cuaj.4586] [Cited by in Crossref: 55] [Cited by in F6Publishing: 32] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Arana A, Margulis AV, McQuay LJ, Ziemiecki R, Bartsch JL, Rothman KJ, Franks B, D'Silva M, Appenteng K, Varas-Lorenzo C, Perez-Gutthann S. Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study. Pharmacotherapy 2018;38:628-37. [PMID: 29723926 DOI: 10.1002/phar.2121] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
2 Berthelot LP, Peyronnet B, Cornu JN, Aublé A, Brassart E, Bigot P, Carrouget J. Do Failure of Posterior Tibial Nerve Stimulation Precludes to Use Sacral Neuromodulation in Patient With Overactive Bladder? Int Neurourol J 2019;23:287-93. [PMID: 31905275 DOI: 10.5213/inj.1938118.059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chen W, Fu C, Wu B, Zhou H, Chen E, Wu Q, Yuan J. Efficacy of non‐pharmacological interventions in females with overactive bladder: A systematic review and network meta‐analysis. Journal of Clinical Nursing. [DOI: 10.1111/jocn.16325] [Reference Citation Analysis]
4 Gratzke C, Chapple C, Mueller ER, Robinson D, Rolland C, Staskin D, Stoelzel M, Maanen RV, Siddiqui E. Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment. European Urology 2019;76:767-79. [DOI: 10.1016/j.eururo.2019.07.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
5 Kreydin EI, Gomes CM, Cruz F. Current pharmacotherapy of overactive bladder. Int Braz J Urol 2021;47:1091-107. [PMID: 34003613 DOI: 10.1590/S1677-5538.IBJU.2021.99.12] [Reference Citation Analysis]
6 Ghijselings L, Hervé F, Van der Aa F, De Wachter S, Pauwaert K, Haddad R, Beeckman D, Pattyn P, Everaert K. Development of a flowchart reflecting the current attitude and approach towards idiopathic overactive bladder treatment in Belgium: A Delphi study. Neurourol Urodyn 2020;39:1781-95. [PMID: 32531082 DOI: 10.1002/nau.24421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Nazir J, Hakimi Z, Guelfucci F, Khemiri A, Fatoye F, Blázquez AMM, González MH. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain. BMC Urol 2018;18:76. [PMID: 30180826 DOI: 10.1186/s12894-018-0390-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
8 Dekhtiar YM, Kostyev FI, Zacheslavsky OM, Kuznietsov DO. Urodynamic characteristics of lower urinary tract of patients with idiopathic overactive bladder. Urol Ann 2019;11:83-6. [PMID: 30787577 DOI: 10.4103/UA.UA_37_18] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Brière R, Versi E, Richard PO, Gratton M, Tu LM. A Preliminary Study on the Impact of Detrusor Overactivity on the Efficacy of Selective Bladder Denervation for the Treatment of Female Refractory Overactive Bladder. Urology 2020;136:88-94. [PMID: 31794815 DOI: 10.1016/j.urology.2019.08.061] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Bernard S, Boucher S, Mclean L, Moffet H. Mobile technologies for the conservative self-management of urinary incontinence: a systematic scoping review. Int Urogynecol J 2020;31:1163-74. [DOI: 10.1007/s00192-019-04012-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
11 Deeks ED. Mirabegron: A Review in Overactive Bladder Syndrome. Drugs 2018;78:833-44. [DOI: 10.1007/s40265-018-0924-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
12 Booth J, Bliss D; International Continence Society Nursing Committee. Consensus statement on bladder training and bowel training. Neurourology and Urodynamics 2020;39:1234-54. [DOI: 10.1002/nau.24345] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Polat Dunya C, Tulek Z, Vızvız GY, Gündüz T, Panicker JN, Kürtüncü M, Eraksoy M. Validation of the Turkish version of the eight-item actionable bladder symptom screening tool in multiple sclerosis. Neurourol Urodyn 2020;39:243-52. [PMID: 31588627 DOI: 10.1002/nau.24177] [Reference Citation Analysis]
14 Yoo R, Spencer M. Continence Promotion and Successful Aging: The Role of the Multidisciplinary Continence Clinic. Geriatrics (Basel) 2018;3:E91. [PMID: 31011126 DOI: 10.3390/geriatrics3040091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Al Dandan HB, Galvin R, McClurg D, Coote S, Robinson K. Management strategies for neurogenic lower urinary tract dysfunction: a qualitative study of the experiences of people with multiple sclerosis and healthcare professionals. Disabil Rehabil 2021;:1-11. [PMID: 33617371 DOI: 10.1080/09638288.2021.1887378] [Reference Citation Analysis]
16 Koch M, Lyatoshinsky P, Mitulovic G, Bodner-Adler B, Lange S, Hanzal E, Umek W. Characteristics of the Urinary Proteome in Women with Overactive Bladder Syndrome: A Case-Control Study. J Clin Med 2021;10:2446. [PMID: 34072980 DOI: 10.3390/jcm10112446] [Reference Citation Analysis]
17 Zhang Y, Wang XD, Song Y, Peng R, Tang T, Li M, Yu Z, Ji Y, Niu J. Epidemiology of Frequent/Urgent Urination in Older Adults in China: A Multicenter, Cross-Sectional Study. Front Public Health 2021;9:669070. [PMID: 34557463 DOI: 10.3389/fpubh.2021.669070] [Reference Citation Analysis]
18 Wagg A. Choosing oral drug therapy for overactive bladder in older people. Expert Opinion on Pharmacotherapy 2018;19:1375-80. [DOI: 10.1080/14656566.2018.1502270] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Fogaing C, Mossa AH, Campeau L. Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder? Curr Urol Rep 2020;21:49. [PMID: 33090278 DOI: 10.1007/s11934-020-01003-z] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Manns K, Khan A, Carlson KV, Wagg A, Baverstock RJ, Trafford Crump R. The use of onabotulinumtoxinA to treat idiopathic overactive bladder in elderly patients is in need of study. Neurourol Urodyn 2021. [PMID: 34618366 DOI: 10.1002/nau.24809] [Reference Citation Analysis]
21 Przydacz M, Golabek T, Dudek P, Skalski M, Sobanski J, Klasa K, Gronostaj K, Dudek D, Chlosta P. Overactive Bladder Symptoms Negatively Affect Sleep Quality of Patients With Depression. Int Neurourol J 2021;25:59-68. [PMID: 33504134 DOI: 10.5213/inj.2040110.055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 . Correction to drug name. Can Urol Assoc J 2017;11:E250. [PMID: 28584565 DOI: 10.5489/cuaj.4722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
23 Ivchenko A, Bödeker RH, Neumeister C, Wiedemann A. Anticholinergic burden and comorbidities in patients attending treatment with trospium chloride for overactive bladder in a real-life setting: results of a prospective non-interventional study. BMC Urol 2018;18:80. [PMID: 30217174 DOI: 10.1186/s12894-018-0394-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Wagg A. Anticholinergics for Overactive Bladder in Frail and Medically Complex Older People: The Case For. Drugs Aging 2018;35:777-80. [PMID: 30097909 DOI: 10.1007/s40266-018-0577-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
25 Reisch B, Das R, Gardner B, Overton K. Cognitive components of behavioral therapy for overactive bladder: a systematic review. Int Urogynecol J 2021. [PMID: 33609161 DOI: 10.1007/s00192-021-04720-2] [Reference Citation Analysis]
26 Elnaggar A, Chendrimada M, Viji M, Dua A. Variations in implementation of bladder training for overactive bladder: an online international survey. Journal of Obstetrics and Gynaecology 2020;40:684-7. [DOI: 10.1080/01443615.2019.1647526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Miget G, Moutounaick M, Kervinio F, Teng M, Chesnel C, Charlanes A, Le Breton F, Amarenco G. [Absorbent products for urinary incontinence management]. Prog Urol 2018;28:953-61. [PMID: 30361139 DOI: 10.1016/j.purol.2018.08.017] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Padilha JF, Avila MA, Seidel EJ, Driusso P. Different electrode positioning for transcutaneous electrical nerve stimulation in the treatment of urgency in women: a study protocol for a randomized controlled clinical trial. Trials 2020;21:166. [PMID: 32046754 DOI: 10.1186/s13063-020-4096-7] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
29 Berke C, Conley MJ, Netsch D, Franklin L, Goodman E, Shephard C, Thompson D. Role of the Wound, Ostomy and Continence Nurse in Continence Care: 2018 Update. J Wound Ostomy Continence Nurs 2019;46:221-5. [PMID: 31083065 DOI: 10.1097/WON.0000000000000529] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
30 Zhou H, Chen W, Yan Y, Wu B, Wang J, Fu C. Efficacy of non-pharmacological interventions in patients with overactive bladder: A protocol for systematic review and network meta-analysis. Nurs Open 2022;9:402-7. [PMID: 34562343 DOI: 10.1002/nop2.1078] [Reference Citation Analysis]
31 Chen LL, Shen YC, Ke CC, Imtiyaz Z, Chen HI, Chang CH, Lee MH. Efficacy of cinnamon patch treatment for alleviating symptoms of overactive bladder: A double-blind, randomized, placebo-controlled trial. Phytomedicine 2021;80:153380. [PMID: 33091856 DOI: 10.1016/j.phymed.2020.153380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Gamé X, Phé V. [First-line treatment for non-neurogenic overactive bladder]. Prog Urol 2020;30:904-19. [PMID: 33220819 DOI: 10.1016/j.purol.2020.08.055] [Reference Citation Analysis]
33 Przydacz M, Golabek T, Dudek P, Lipinski M, Chlosta P. Prevalence and bother of lower urinary tract symptoms and overactive bladder in Poland, an Eastern European Study. Sci Rep 2020;10:19819. [PMID: 33188254 DOI: 10.1038/s41598-020-76846-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
34 Mossa A, Velasquez Flores M, Nguyen H, Cammisotto PG, Campeau L. Beta-3 Adrenoceptor Signaling Pathways in Urothelial and Smooth Muscle Cells in the Presence of Succinate. J Pharmacol Exp Ther 2018;367:252-9. [PMID: 30104323 DOI: 10.1124/jpet.118.249979] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
35 Brucker BM, Lee RK, Newman DK. Optimizing Nonsurgical Treatments of Overactive Bladder in the United States. Urology 2020;145:52-9. [PMID: 32598892 DOI: 10.1016/j.urology.2020.06.017] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Przydacz M, Chłosta M, Belch Ł, Czech AK, Wiatr T, Gronostaj K, Lipinski M, Chłosta P. Treatment patterns for lower urinary tract symptoms and overactive bladder in an Eastern European country: a nationwide population-representative survey. Cent European J Urol 2021;74:382-7. [PMID: 34729230 DOI: 10.5173/ceju.2021.0087] [Reference Citation Analysis]
37 Makhani A, Thake M, Gibson W. Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient. Clin Interv Aging 2020;15:575-81. [PMID: 32368024 DOI: 10.2147/CIA.S174402] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
38 Przydacz M, Campeau L, Walter JE, Corcos J. How long do we have to treat overactive bladder syndrome (OAB)? A questionnaire survey of Canadian urologists and gynecologists. Can Urol Assoc J 2018. [PMID: 29787370 DOI: 10.5489/cuaj.5032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
39 Sinha S, Vasudeva P, Bharadwaj S, Mittal A. Role of Pelvic Organ Crosstalk in Dysfunction of the Bowel and Bladder. Curr Bladder Dysfunct Rep. [DOI: 10.1007/s11884-022-00645-8] [Reference Citation Analysis]
40 Aharony S, Przydacz M, Van Ba OL, Corcos J. Does asymptomatic bacteriuria increase the risk of adverse events or modify the efficacy of intradetrusor onabotulinumtoxinA injections? Neurourology and Urodynamics 2020;39:203-10. [DOI: 10.1002/nau.24169] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
41 Van Rensburg JA, Cassim F. The Non-neurogenic Overactive Bladder: an Update. Curr Obstet Gynecol Rep 2018;7:139-45. [DOI: 10.1007/s13669-018-0248-0] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Teixeira Alve A, Azevedo Garcia P, Henriques Jácomo R, Batista de Sousa J, Borges Gullo Ramos Pereira L, Barbaresco Gomide Mateus L, Gomes de Oliveira Karnikoskwi M. Effectiveness of transcutaneous tibial nerve stimulation at two different thresholds for overactive bladder symptoms in older women: a randomized controlled clinical trial. Maturitas 2020;135:40-6. [PMID: 32252963 DOI: 10.1016/j.maturitas.2020.02.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Gamé X, Phé V. [Treatment for refractory non-neurogenic overactive bladder]. Prog Urol 2020;30:920-30. [PMID: 33220820 DOI: 10.1016/j.purol.2020.09.004] [Reference Citation Analysis]
44 Neu S, Locke J, Goldenberg M, Herschorn S. Urethrovaginal fistula repair with or without concurrent fascial sling placement: A retrospective review. Can Urol Assoc J 2021;15:E276-80. [PMID: 33119501 DOI: 10.5489/cuaj.6786] [Reference Citation Analysis]
45 Bravo-Balado A, Plata M, Trujillo CG, Caicedo JI, Serrano A, Ramos A, Cataño JG. Is the development of clinical practice guidelines for non-neurogenic overactive bladder trustworthy? A critical appraisal using the Appraisal of Guidelines, Research and Evaluation (AGREE) II instrument. BJU Int 2019;123:921-2. [PMID: 30667143 DOI: 10.1111/bju.14684] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
46 Phé V, Gamé X. [Male non-neurogenic overactive bladder]. Prog Urol 2020;30:880-6. [PMID: 33220816 DOI: 10.1016/j.purol.2020.09.005] [Reference Citation Analysis]
47 Lenger SM, Chu CM, Ghetti C, Hardi AC, Lai HH, Pakpahan R, Lowder JL, Sutcliffe S. Adult female urinary incontinence guidelines: a systematic review of evaluation guidelines across clinical specialties. Int Urogynecol J 2021. [PMID: 33881602 DOI: 10.1007/s00192-021-04777-z] [Reference Citation Analysis]
48 Przydacz M, Dudek P, Golabek T, Chlosta P. Relationship between Lower Urinary Tract Symptoms and Treatment-Related Behavior in an Eastern European Country: Findings from the LUTS POLAND Study. Int J Environ Res Public Health 2021;18:E785. [PMID: 33477665 DOI: 10.3390/ijerph18020785] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]